Detalles de la búsqueda
1.
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
J Urol
; 206(2): 240-251, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33835866
2.
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(12): 1351-60, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25273343
3.
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
Lancet Oncol
; 15(11): 1269-78, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25273342
4.
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.
Eur Urol Focus
; 7(5): 1084-1091, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33168461
5.
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma.
Eur J Cancer
; 138: 202-211, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32905959
6.
Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.
Eur Urol Oncol
; 2(1): 12-20, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30929841
7.
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Eur Urol
; 76(1): 73-81, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30910346
Resultados
1 -
7
de 7
1
Próxima >
>>